Comparative Pharmacology
Head-to-head clinical analysis: ESTRACE versus TACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRACE versus TACE.
ESTRACE vs TACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol, a form of estrogen, binds to and activates nuclear estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent physiological effects including development of secondary sexual characteristics, regulation of reproductive cycle, and effects on bone density, lipid metabolism, and cardiovascular system.
TACE (Transcatheter Arterial Chemoembolization) is not a drug but a procedure combining intra-arterial chemotherapy and embolization. Chemotherapeutic agents (e.g., doxorubicin, cisplatin) are delivered directly to tumor-feeding arteries, inducing cytotoxicity, while embolic agents (e.g., lipiodol, microspheres) occlude blood flow, causing ischemia and enhancing drug retention.
1 to 2 mg orally once daily for continuous estrogen replacement; 0.1% cream applied vaginally 1 to 2 times daily for atrophic vaginitis.
Transarterial chemoembolization (TACE) with doxorubicin: 50-75 mg/m² or up to 150 mg total dose, administered via hepatic artery injection, repeated every 4-6 weeks as tolerated.
None Documented
None Documented
Terminal half-life: 13-27 hours (mean 19 hours); clinical context: supports once-daily dosing for hormone replacement.
Variable depending on the drug; for doxorubicin, terminal half-life is 24-36 hours, clinically relevant for systemic toxicity.
Renal: 50-80% as glucuronide and sulfate conjugates; fecal: 10-20%; biliary: minor (<5%).
TACE is not a specific drug but a procedure (transarterial chemoembolization). The chemotherapeutic agents used (e.g., doxorubicin, cisplatin, mitomycin C) are typically eliminated via hepatic metabolism and biliary excretion, with renal excretion as a minor route (<10% for doxorubicin).
Category C
Category C
Estrogen
Estrogen